Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570297 · ClinicalTrials.gov registry record
Genetic Influences of Albuterol Response In Children With Bronchiolitis
A clinical trial, sponsored by Connecticut Children's Medical Center.
- Completed
- Registry status
- 54
- Enrollment target
NCT00570297 is a clinical trial that has completed, run by Connecticut Children's Medical Center. The registered enrollment target is 54 participants.
The verdict
NCT00570297 has completed, sponsored by Connecticut Children's Medical Center.
- COMPLETED
- Registry status
- 54 participants
- Enrollment target
Study Summary
Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 hospitalizations per year in the U.S. Recently, genetic variations of the β2-adrenergic receptor (β2-AR) have been shown to influence response to β2-AR agonist therapy in children with asthma. We suspect that genetic variations of the β2-AR also affect response to β2-AR agonist therapy in children with bronchiolitis.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2007-12 |
| Est. Completion | 2018-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570297
The ClinicalTrials.gov registry entry for NCT00570297 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connecticut Children's Medical Center, which has 55 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00570297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570297 about?
NCT00570297 is a clinical study titled "Genetic Influences of Albuterol Response In Children With Bronchiolitis". Bronchiolitis is a significant cause of morbidity and hospitalization in children, accounting for approximately 125,000 hospitalizations per year in the U.S. Recently, genetic variations of the β2-adrenergic receptor (β2-AR) have been shown to influence response to β2-AR agonist therapy in children ...
What is the current status of trial NCT00570297?
This trial is currently completed. The enrollment target is 54 participants. The study started on 2007-12. Estimated completion is 2018-04.
Who is sponsoring clinical trial NCT00570297?
This trial is sponsored by Connecticut Children's Medical Center, which has 55 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.